ClinicalTrials.gg
RecruitingNCT06701396Updated Nov 22, 2024

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant

A Phase 3 interventional study of Tasimelteon and Placebo in Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm and Chronobiology Disorders, sponsored by Vanda Pharmaceuticals. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-22.

Primary conditionSleep Disorders, Circadian RhythmRegistry: Sleep Wake DisordersReclassifiedWhy we changed it
Registry
Sleep Wake Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sleep Disorders, Circadian Rhythm
Why
  1. The study's listed conditions name Sleep Disorders, Circadian Rhythm, a narrower term within Sleep Wake Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a double-blind, randomized, two-period crossover study to evaluate the efficacy and safety of a single oral dose of tasimelteon and matching placebo in male and female subjects with DSWPD and the CRY1Δ11 variant.

02

Conditions studied

  • Sleep Wake Disorders
  • Sleep Disorders, Circadian Rhythm
  • Chronobiology Disorders
  • Gene Mutations and Other Alterations Nec

Browse trials for

03

In context

Sleep Disorders, Circadian Rhythm Reclassified

135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.

This study's planned enrollment of 60 is close to the median of 59 across 102 interventional studies indexed under Sleep Disorders, Circadian Rhythm.

Browse Sleep Disorders, Circadian Rhythm studies →

Lead sponsor

Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.

Compared within Sleep Disorders, Circadian Rhythm, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sleep Wake Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability and acceptance to provide written .
  • A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).
  • Carrier of CRY1Δ11 variant.
  • Men or women between 18 - 75 years, inclusive.
  • (BMI) of ≥ 18 and ≤ 40 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.
  • Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.
  • A positive test for substances of abuse.
  • Current tobacco user.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Tasimelteon

    Drug: Tasimelteon

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Latency to Persistent Sleep, as measured by polysomnography.

    Time frame: Two Nights

07

Study locations

1 of 1 sites recruiting
  • Vanda Investigational Site
    Çankaya, Ankara 06800, Turkey
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Jun 2025, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2024
First posted
Nov 22, 2024
StartActual
Oct 8, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2025
Last update
Nov 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06701396
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Oct 8, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Nov 22, 2024

Study contacts

Vanda Pharmaceuticals Inc.
Contact
VEC162@vandapharma.com
202-734-3400

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion